Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Abstract

The triazole Bay R 3783 was compared with fluconazole, itraconazole, ketoconazole, and amphotericin B in rodent models of superficial and systemic candidiasis, meningocerebral cryptococcosis, and pulmonary aspergillosis. Overall, Bay R 3783 was comparable or slightly superior to fluconazole and markedly superior to itraconazole and ketoconazole in both survival and short-term organ load experiments in models of candidiasis and cryptococcosis but was less effective than amphotericin B. Of the antifungal agents tested, only Bay R 3783 and itraconazole showed any efficacy in the model of pulmonary aspergillosis.

• Authors: R F Hector, E Yee
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 34 Issue 3 Pg. 448-54 (Mar 1990) ISSN: 0066-4804 [Print] United States
• PMID: 2159257 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antifungal Agents
• Pharmaceutical Vehicles
• Triazoles
• Bay R 3783
• Itraconazole
• Amphotericin B
• Fluconazole
• Ketoconazole

Topics

• Administration, Oral
• Amphotericin B (pharmacology)
• Animals
• Antifungal Agents (pharmacology)
• Aspergillosis (drug therapy)
• Candidiasis (drug therapy)
• Cryptococcosis (drug therapy)
• Disease Models, Animal
• Drug Administration Schedule
• Evaluation Studies as Topic
• Female
• Fluconazole (pharmacology)
• Itraconazole
• Ketoconazole (analogs & derivatives, pharmacology)
• Lung Diseases, Fungal (drug therapy)
• Male
• Meningitis (drug therapy)
• Mice
• Pharmaceutical Vehicles
• Rats
• Rats, Inbred Strains
• Triazoles (pharmacology, therapeutic use)